Literature DB >> 19840957

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.

C J Zappala1, P I Latsi, A G Nicholson, T V Colby, D Cramer, E A Renzoni, D M Hansell, R M du Bois, A U Wells.   

Abstract

In therapeutic studies in idiopathic pulmonary fibrosis (IPF), the low prevalence of significant change in pulmonary functional tests (PFTs) has been a major constraint. The prognostic value of "marginal" changes in PFTs in IPF and fibrotic non-specific interstitial pneumonia (NSIP) was evaluated. In patients with biopsy-proven IPF (n = 84) and NSIP (n = 72), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (D( L,CO)) trends at 6 months were categorised as "significant" (FVC >10%; D(L,CO) >15%) or "marginal" (FVC 5-10%; D(L,CO) 7.5-15%). Proportional hazards analysis and time-dependent receiver operating characteristic methodology were used to examine PFT trends against mortality. In IPF, reductions in FVC were significant in 22 cases (26%) and marginal in 19 cases (23%). Mortality was higher in patients with a significant decline in FVC (hazard ratio (HR) 2.80, 95% CI 1.54-5.06; p<0.001) and those with a marginal decline in FVC (HR 2.31, 95% CI 1.19-4.50; p = 0.01) than in those with stable disease. Progression-free survival was lower when the decline in FVC was marginal than in stable disease (HR 2.34, 95% CI 1.19-4.60; p = 0.01). Marginal changes in D(L,CO) in IPF and marginal changes in FVC and D (L,CO) in fibrotic NSIP did not provide useful prognostic information. Marginal change in FVC in IPF denotes a poor outcome. These findings are applicable to clinical practice and to the selection of patients with more progressive disease for therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840957     DOI: 10.1183/09031936.00155108

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  93 in total

Review 1.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

2.  Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2015-09-15       Impact factor: 2.444

Review 3.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

4.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

5.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Meilan Han; Rekha Vij; Imre Noth; Eric L Eisenstein; Kevin J Anstrom; Kevin K Brown; Diane Fairclough
Journal:  Respir Med       Date:  2012-07-15       Impact factor: 3.415

6.  Exposure to Ambient Particulate Matter Is Associated With Accelerated Functional Decline in Idiopathic Pulmonary Fibrosis.

Authors:  Christopher J Winterbottom; Rupal J Shah; Karen C Patterson; Maryl E Kreider; Reynold A Panettieri; Belinda Rivera-Lebron; Wallace T Miller; Leslie A Litzky; Trevor M Penning; Krista Heinlen; Tara Jackson; A Russell Localio; Jason D Christie
Journal:  Chest       Date:  2017-08-09       Impact factor: 9.410

7.  Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Williamson Z Bradford; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; David Kardatzke; Talmadge E King; Lisa H Lancaster; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Jeffrey J Swigris; Paul W Noble
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

8.  Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Authors:  Jennifer M Wang; Scott H Robertson; Ziyi Wang; Mu He; Rohan S Virgincar; Geoffry M Schrank; Rose Marie Smigla; Thomas G O'Riordan; John Sundy; Lukas Ebner; Craig R Rackley; Page McAdams; Bastiaan Driehuys
Journal:  Thorax       Date:  2017-08-31       Impact factor: 9.139

Review 9.  The diagnosis and treatment of idiopathic pulmonary fibrosis.

Authors:  Jürgen Behr
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

10.  Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach.

Authors:  Peter Korsten; Katharina Strohmayer; Robert P Baughman; Nadera J Sweiss
Journal:  Clin Pulm Med       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.